drug · small molecule

KOSELUGO

updated 3mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neurofibromatosis type 1 and neoplasm and 20 investigational indications.

targets

Dual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase; MEK1/2Dual specificity mitogen-activated protein kinase kinase 1

all catalysts(0)

nothing on the calendar yet

Trials studying KOSELUGO

phase2Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PNactive not recruitingn=36
phase2National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancercompletedn=423
phase1AZD9291 in Combination With Ascending Doses of Novel Therapeuticsactive not recruitingn=344
phase1Selumetinib and Olaparib in Solid Tumorsactive not recruitingn=90
phase3Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromasactive not recruitingn=145
phase2AMTEC IIT: Phase 2 Multiarm Study in TNBCterminatedn=24
phase1Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromasactive not recruitingn=24
phase1A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)active not recruitingn=32

more trials →

News(0)

no news has mentioned this drug yet

brand

KOSELUGO

generic

SELUMETINIB

MOA

12.1 Mechanism of Action Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Both MEK and ERK are critical components of the RAS-regulated RAF-MEK-ERK pathway, which is often activated in different types of cancers. In genetically modified mouse models of NF1 that generate neurofibromas that recapitulate the genotype and phenotype of human NF1, oral dosing of selumetinib inhibited ERK phosphorylation, and reduced neurofibroma numbers, volume, and proliferation.

indication

1 INDICATIONS AND USAGE KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) [see Dosage and Administration (2) ]. KOSELUGO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 11m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

KOSELUGO

updated 3mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neurofibromatosis type 1 and neoplasm and 20 investigational indications.

targets

Dual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase; MEK1/2Dual specificity mitogen-activated protein kinase kinase 1

all catalysts(0)

nothing on the calendar yet

Trials studying KOSELUGO

phase2Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PNactive not recruitingn=36
phase2National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancercompletedn=423
phase1AZD9291 in Combination With Ascending Doses of Novel Therapeuticsactive not recruitingn=344
phase1Selumetinib and Olaparib in Solid Tumorsactive not recruitingn=90
phase3Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromasactive not recruitingn=145
phase2AMTEC IIT: Phase 2 Multiarm Study in TNBCterminatedn=24
phase1Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromasactive not recruitingn=24
phase1A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)active not recruitingn=32

more trials →

News(0)

no news has mentioned this drug yet

brand

KOSELUGO

generic

SELUMETINIB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 11m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

KOSELUGO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying KOSELUGO

News(0)

Report a data issue

comments(0)

KOSELUGO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying KOSELUGO

News(0)

Report a data issue

comments(0)